TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25170230

Group type: EXPERIMENTAL
Intervention: Furazolidone-based triple therapy (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 7 days
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Furazolidone-based quadruple therapy (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 7 days
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Furazolidone-based triple therapy (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 10 days
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Furazolidone-based quadruple therapy (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 10 days
Number of subjects: 720
Study: 23176379

Group type: EXPERIMENTAL
Intervention: Allicor (time-released garlic-based drug)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 20581879

Group type: EXPERIMENTAL
Intervention: Late mRNA-based (NucliSens CMV pp67) anti-HCMV treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: PCR-based preemptive HCMV-directed antiviral therapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both late mRNA-based and PCR-based therapies
Number of subjects: 130
Study: 18463998

Group type: EXPERIMENTAL
Intervention: Psychosocial treatments (four types) for cocaine dependence
Number of subjects: 487

Group type: COMPARATOR
Intervention: Non-protocol services (additional treatment services)
Number of subjects: 487
Study: 16527699

Group type: EXPERIMENTAL
Intervention: High-resolution colonoscopy with chromoscopy (HRC)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 203
Study: 12954249

Group type: EXPERIMENTAL
Intervention: Non-bridging external fixator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bridging external fixator
Number of subjects: 0
Study: 10731499

Group type: EXPERIMENTAL
Intervention: Strontium alone (load A)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Strontium with 35 g lactose (load B)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Strontium with 17.5 g glucose and 17.5 g galactose (load C)
Number of subjects: 11
Study: 8941092

Group type: EXPERIMENTAL
Intervention: Low-dose heparin infusion (250 IU primed, 600 IU/h continuous)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heparin/insulin period
Number of subjects: 11
Study: 1490690

Group type: EXPERIMENTAL
Intervention: Glipizide 0.5 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glipizide 1.0 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glipizide 2.5 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 3917652

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: TAM + ftorafur (FT‐E)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: TAM + FT‐E + Adriamycin
Number of subjects: 193
Study: 31333058

Group type: EXPERIMENTAL
Intervention: Ultrasonic propulsion (350 kHz frequency, ≤200 W/cm2 focal intensity, ≤3‐second bursts per push)
Number of subjects: 18
Study: 29577536

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Insulin pump therapy (control)
Number of subjects: 60
Study: 27309523

Group type: EXPERIMENTAL
Intervention: A-polyaminopropyl biguanide + polyquaternium
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: POLYQUAD + Aldox
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: alexidine + polyquaternium‐1
Number of subjects: 236

Group type: COMPARATOR
Intervention: hydrogen peroxide
Number of subjects: 236
Study: 26842195

Group type: EXPERIMENTAL
Intervention: Colonic J pouch (CJP) neorectum
Number of subjects: 42

Group type: COMPARATOR
Intervention: Straight anastomosis (SA)
Number of subjects: 42
Study: 23924302

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including universal nutritional screening, oral nutritional supplements, red trays, and additional feeding support
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 120
Study: 20388217

Group type: EXPERIMENTAL
Intervention: Dietary fasting for 12 hours prior to the fasting trial
Number of subjects: 22
Study: 18082300

Group type: EXPERIMENTAL
Intervention: Vision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vision+Action
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Action
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grip
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shape
Number of subjects: 0
Study: 16137945

Group type: EXPERIMENTAL
Intervention: Calcium intake of 1,200-1,500 mg/day (WHO, North America, Europe)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium intake of 800 mg/day (Japan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D intake of 10-20 microg/day (most countries)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin D intake of 5 microg/day (Japan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General dietary guidelines (optimal body weight, adequate protein intake, balanced diet, avoiding excess sodium and caffeine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin K and other vitamins and minerals intake guidelines (not included in most countries)
Number of subjects: 0
Study: 12900301

Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg) with enhanced community-based skills training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Haloperidol (low dose)
Number of subjects: 63
Study: 10469192

Group type: COMPARATOR
Intervention: Omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40
Number of subjects: 243
Study: 7549447

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (0.3%)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rifamycin (1%)
Number of subjects: 41
Study: 2332744

Group type: EXPERIMENTAL
Intervention: Appointment scheduling and reminder postcards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (examined, informed about mammography, instructed to make an appointment)
Number of subjects: 0
Study: 74660

Group type: EXPERIMENTAL
Intervention: Salt restriction
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 31

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 31
Study: 30860603

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) alcohol to a target breath alcohol concentration (BrAC) of 0.06 g/dl
Number of subjects: 0
Study: 29125558

Group type: EXPERIMENTAL
Intervention: B’more Healthy Communities for Kids (BHCK) intervention
Number of subjects: 365
Study: 24785367

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation for 8 hours post-training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (normal attire) for 8 hours post-training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (normal attire)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation and Control
Number of subjects: 28
Study: 23363580

Group type: EXPERIMENTAL
Intervention: 5% sucrose diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: 15% sucrose diet
Number of subjects: 13
Study: 22155721

Group type: EXPERIMENTAL
Intervention: Online completion of the Fatigue Symptom Inventory
Number of subjects: 1969

Group type: COMPARATOR
Intervention: Offline completion of the Fatigue Symptom Inventory
Number of subjects: 1969

Group type: EXPERIMENTAL
Intervention: Online completion of the SF-12v2
Number of subjects: 1969

Group type: COMPARATOR
Intervention: Offline completion of the SF-12v2
Number of subjects: 1969

Group type: EXPERIMENTAL
Intervention: Online completion of the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 1969

Group type: COMPARATOR
Intervention: Offline completion of the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 1969

Group type: EXPERIMENTAL
Intervention: Online completion of the single-item fatigue measure
Number of subjects: 1969

Group type: COMPARATOR
Intervention: Offline completion of the single-item fatigue measure
Number of subjects: 1969
Study: 19200175

Group type: EXPERIMENTAL
Intervention: APL 200 mg bid
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: APL 400 mg bid
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: APL 800 mg qd
Number of subjects: 191

Group type: COMPARATOR
Intervention: 3TC/ZDV
Number of subjects: 191
Study: 16673683

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 176
Study: 15288626

Group type: COMPARATOR
Intervention: Group A (control group) - standard Vicryl ligation
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Group B - Vicryl ligation followed by Prolene oversewing
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Group C - Ethibond ligation
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Group D - Ethibond ligation followed by Prolene oversewing
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Endothelial closure (Groups B and D combined)
Number of subjects: 379
Study: 11319192

Group type: EXPERIMENTAL
Intervention: Coumarins with target INR of 2.1 to 4.8 during angioplasty and 6-month follow-up
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Optimal anticoagulation (INR in target range for at least 70% of follow-up time)
Number of subjects: 530
Study: 9037327

Group type: EXPERIMENTAL
Intervention: Mibefradil 50, 100, and 150 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nifedipine GITS 30, 60, and 90 mg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg alone or combined with lisinopril 20 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 71
Study: 8294833

Group type: EXPERIMENTAL
Intervention: Upper arm tourniquet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Forearm tourniquet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Forearm tourniquet (in clinical cases)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tourniquet times less than 30 minutes
Number of subjects: 40
Study: 2883695

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.057 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.029 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diazepam (0.286 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.000 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.028 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.014 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diazepam (0.143 mg/kg)
Number of subjects: 8
Study: 29595304

Group type: EXPERIMENTAL
Intervention: Writing a letter to their future self (either three months or 20 years into the future)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26180052

Group type: EXPERIMENTAL
Intervention: HD-tDCS at 1 mA for 10 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HD-tDCS at 1 mA for 20 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HD-tDCS at 2 mA for 10 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HD-tDCS at 2 mA for 20 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Stimulation of LTA and DLPFC
Number of subjects: 27
Study: 24911577

Group type: EXPERIMENTAL
Intervention: Lorediplon 5 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lorediplon 10 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lorediplon 1 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Zolpidem 10 mg (active control)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22419350

Group type: EXPERIMENTAL
Intervention: POIO (preoperative and intraoperative dose)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: POIOPO (preoperative, intraoperative, and postoperative doses)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: LA (local application)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: IO (intraoperative dose only)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: IOPO (intraoperative and postoperative doses)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 240
Study: 20804368

Group type: EXPERIMENTAL
Intervention: Cs-4 (Cordyceps sinensis) 333 mg, taken 3 times a day for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18000183

Group type: EXPERIMENTAL
Intervention: Coccinia cordifolia extract (1 g alcoholic extract for 90 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15930077

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy plus olanzapine (mean dose 8.83 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dialectical behavior therapy plus placebo
Number of subjects: 60
Study: 12830102

Group type: EXPERIMENTAL
Intervention: Community-based nurse case managers
Number of subjects: 106
Study: 10584567

Group type: EXPERIMENTAL
Intervention: MPA 1,200 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: MPA 600 mg
Number of subjects: 73
Study: 8674893

Group type: EXPERIMENTAL
Intervention: Low-fat, low-cholesterol diet, high polyunsaturated/saturated fatty acid ratio, and calorie restriction
Number of subjects: 14

Group type: COMPARATOR
Intervention: No dietary change
Number of subjects: 14
Study: 2060176

Group type: EXPERIMENTAL
Intervention: Disodium clodronate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 6863091

Group type: EXPERIMENTAL
Intervention: Caffeine (500 mg) administered orally
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31752105

Group type: EXPERIMENTAL
Intervention: Vegan Diet (VD)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Meat-Rich Diet (MD)
Number of subjects: 53
Study: 29020589

Group type: EXPERIMENTAL
Intervention: ChAd3‐EBO‐Z vaccine
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: rVSV∆G‐ZEBOV‐GP vaccine
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 26560243

Group type: COMPARATOR
Intervention: Adaptive control (Ossur Rheo Knee II)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active control (Ossur Power Knee II)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Passive control (existing knee)
Number of subjects: 12
Study: 23431996

Group type: EXPERIMENTAL
Intervention: ATG-Fresenius (9 mg/kg body weight)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no induction therapy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ATG-Fresenius
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 20584798

Group type: EXPERIMENTAL
Intervention: Early continuous positive airway pressure (CPAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 39
Study: 19584690

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced cyclosporine A (CsA) (trough level 3-8 ng/mL)
Number of subjects: 176

Group type: COMPARATOR
Intervention: MMF (3 g/day) with standard CsA
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 176

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 176
Study: 15991090

Group type: EXPERIMENTAL
Intervention: lipo‐PGE 1
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (methylprednisolone only)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 128
Study: 12514304

Group type: EXPERIMENTAL
Intervention: CLA-mix (8.0 g daily, 76% pure CLA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Safflower oil (placebo, 8.0 g daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: t10c12-CLA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: c9t11-CLA
Number of subjects: 21
Study: 10561291

Group type: EXPERIMENTAL
Intervention: CODE (cisplatin, vincristine, doxorubicin, etoposide)
Number of subjects: 219

Group type: COMPARATOR
Intervention: CAV/EP (cyclophosphamide, doxorubicin, vincristine/etoposide, cisplatin)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: CODE
Number of subjects: 219

Group type: COMPARATOR
Intervention: CAV/EP
Number of subjects: 219
Study: 8762417

Group type: EXPERIMENTAL
Intervention: Zhikang Oral Liquid (ZK)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 1676675

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg (B5)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg (B10)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg (B20)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (A50)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (A100)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg (N40)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isoprenaline-induced tachycardia with bisoprolol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isoprenaline-induced tachycardia with atenolol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isoprenaline-induced tachycardia with nadolol
Number of subjects: 7
Study: 6304360

Group type: EXPERIMENTAL
Intervention: American Heart Association Hyperlipidemia Diet C (n = 20)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-fat, high-fiber, complex carbohydrate diet (similar to Pritikin Maintenance Diet, n = 25)
Number of subjects: 45
Study: 31502228

Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 279
Study: 31022481

Group type: EXPERIMENTAL
Intervention: Supervised exercise program delivered in a facility-based setting
Number of subjects: 500

Group type: COMPARATOR
Intervention: Telerehabilitation exercise program delivered in a home-based setting
Number of subjects: 500
Study: 28893753

Group type: EXPERIMENTAL
Intervention: Venous stenting
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 130
Study: 27007998

Group type: EXPERIMENTAL
Intervention: Ambroxol oral tablets
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ambroxol orally-disintegrating tablets
Number of subjects: 100
Study: 24035344

Group type: EXPERIMENTAL
Intervention: Ketamine 0.41 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketamine 0.71 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 8
Study: 21993937

Group type: EXPERIMENTAL
Intervention: Laparoscopic duodenojejunal bypass with sleeve gastrectomy
Number of subjects: 38
Study: 18981187

Group type: EXPERIMENTAL
Intervention: Peripheral sensory stimulation (2 hours of simultaneous electrical stimulation over the median and ulnar nerves at the wrist)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-control (stimulation to the level of perception)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Peripheral sensory stimulation and Sham-control
Number of subjects: 20
Study: 17414939

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.375 mg/d to a maximum tolerated dose of ≤4.5 mg/d over a 6-week period)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 144
Study: 15708053

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (100 mg) taken 1 to 2 hours before VCD use
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (VCD alone)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination therapy (sildenafil + VCD)
Number of subjects: 31
Study: 12218949

Group type: EXPERIMENTAL
Intervention: Heparin (100 IU/kg body weight, subcutaneous for 6 days)
Number of subjects: 49
Study: 9593384

Group type: EXPERIMENTAL
Intervention: Heparin surface-modified (HSM) intraocular lenses (IOLs)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA) intraocular lenses (IOLs)
Number of subjects: 25
Study: 8829890

Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg
Number of subjects: 102
Study: 2212123

Group type: EXPERIMENTAL
Intervention: Intradermal platelet-activating factor (PAF-acether)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet activating factor antagonist BN52063
Number of subjects: 0
Study: 81986

Group type: EXPERIMENTAL
Intervention: Azathioprine continued
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control tablet substituted
Number of subjects: 51
Study: 31651084

Group type: EXPERIMENTAL
Intervention: Foot orthoses plus prescribed footwear
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prescribed footwear alone
Number of subjects: 46
Study: 31495898

Group type: EXPERIMENTAL
Intervention: Liquid Emulsion (LE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Solid Emulsion (SE)
Number of subjects: 15
Study: 30738659

Group type: EXPERIMENTAL
Intervention: Early rising BMI trajectory group
Number of subjects: 410

Group type: COMPARATOR
Intervention: Late rising BMI trajectory group
Number of subjects: 410

Group type: COMPARATOR
Intervention: Normal BMI trajectory group
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: BMI trajectory groups comparison
Number of subjects: 410
Study: 28526014

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 4768

Group type: EXPERIMENTAL
Intervention: Antihyperglycaemia therapy
Number of subjects: 4768

Group type: COMPARATOR
Intervention: No lipid-lowering therapy
Number of subjects: 4768
Study: 22978697

Group type: EXPERIMENTAL
Intervention: Metal-ceramic crown (MC) made from a Pd‐Au‐Ag‐Sn‐In alloy and a glass‐ceramic veneer
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Non-veneered (glazed) lithium disilicate glass‐ceramic crown (LDC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Veneered lithia disilicate glass‐ceramic crown (LDC/V)
Number of subjects: 31